This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA published a report for Pharmaceutical Care Management Association on the potential effects on proposed changes to the definition of Medicare Part D prices. To read the report, click the link below.
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...
This study used a consensus-based approach to identify high-impact solutions for reducing racial and ethnic health disparities in lupus. Through a literature...
Last year, Regeneron took to trial its case alleging exclusionary conduct through bundled rebates by competitor Amgen. The jury found for Regeneron, awarding...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
